Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council
M. V. Ezhov,
V. V. Kukharchuk,
I. V. Sergienko,
N. M. Akhmedzhanov,
M. I. Voevoda,
V. S. Gurevich,
V. V. Kashtalap,
V. O. Konstantinov,
V. V. Skibitsky,
I. I. Shaposhnik https://doi.org/10.20996/1819-6446-2021-02-02
Abstract
The meeting of the expert council of cardiologists-lipidologists, organized with the support of Novartis and dedicated to the discussion of the existing system of medical care for patients with familial hypercholesterolemia / mixed dyslipidemia, the modern evidence base for lipid-lowering therapy and the practical value of the strategy of early combined lipid-lowering therapy for doctors and these categories of patients was held in Moscow on November 11, 2020.
About the Authors
M. V. EzhovRussian Federation
Marat V. Ezhov
eLibrary SPIN 7623-2135
V. V. Kukharchuk
Russian Federation
Valery V. Kukharchuk
eLibrary SPIN 6776-1083
I. V. Sergienko
Russian Federation
Igor V. Sergienko
eLibrary SPIN 1643-1586
N. M. Akhmedzhanov
Russian Federation
Nadir M. Akhmedzhanov
eLibrary SPIN 2987-9035
M. I. Voevoda
Russian Federation
Mikhail I. Voevoda
eLibrary SPIN 6133-1780
V. S. Gurevich
Russian Federation
Viktor S. Gurevich
eLibrary SPIN 3267-2301
V. V. Kashtalap
Russian Federation
Vasily V. Kashtalap
eLibrary SPIN 8816-7409
V. O. Konstantinov
Russian Federation
Vladimir O. Konstantinov
eLibrary SPIN 8720-1582
V. V. Skibitsky
Russian Federation
Vitaly V. Skibitsky
eLibrary SPIN 3595-5662
I. I. Shaposhnik
Russian Federation
Igor I. Shaposhnik
eLibrary SPIN 3184-5994
References
1. Healthcare in Russia 2019. Statistical Book Moscow: Rosstat; 2019 (In Russ.)
2. Heart and Circulatory Disease Statistics 2019. Published by the BHF in collaboration with the Institute of Applied Health Research at the University of Birmingham [cited by Jan 10, 2021]. Available from: www.bhf.org.uk/statistics.
3. State of Health in the EU. Germany. Country Health Profile 2019 [cited by Jan 10, 2021]. Available from: http://www.oecd.org/publications/germany-country-health-profile-2019-36e21650-en.htm.
4. Boytsov S.A., Shalnova S.A., Deev A.D. Mortality from cardiovascular diseases in the Russian Federation and possible mechanisms of its change. Journal of Neurology and Psychiatry. S.S. Korsakov. 2018;118(8):98-103 (In Russ.) DOI:10.17116/jnevro201811808198.
5. Boytsov S.A., Demkina A.E., Oshchepkova E.V., Dolgusheva Yu.A. Progress and Problems of Practical Cardiology in Russia at the Present Stage. Kardiologiia. 2019;59(3):53-9 (In Russ.) DOI:10.18087/cardio.2019.3.10242.
6. Relationship between baseline risk factors and coronary heart disease and total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med. 1986;15(3):254-73. DOI:10.1016/0091-7435(86)90045-9.
7. Cardiovascular prevention 2017. Russian national guidelines. Russian Journal of Cardiology 2018;23(6):7-122 (In Russ.) DOI:10.15829/1560-4071-2018-6-7-122.
8. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. DOI:10.1016/j.atherosclerosis.2019.08.014.
9. Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, VII revision. Atherosclerosis and Dyslipidemia. 2020;1:7-34 (In Russ.)
10. 2018/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol; A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-e350. DOI:10.1016/j.jacc.2018.11.003.
11. Methodical recommendations for the organization of medical care for patients with hereditary atherogenic disorders of lipid metabolism in the subjects of the Russian Federation. Atherosclerosis and Dyslipidemia. 2016; 4: 15-20 (In Russ.)
12. Ezhov M.V., Bliznyuk S.A., Tmoyan N.A., et al. Register of patients with familial hypercholesterolemia and patients with very high cardiovascular risk with insufficient effectiveness of lipid-lowering therapy (RENAISSANCE). Russian Journal of Cardiology. 2019;24(5):7-13 (In Russ.) DOI:10.15829/1560-4071-2019-5-7-13.
Review
For citations:
Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Akhmedzhanov N.M., Voevoda M.I., Gurevich V.S., Kashtalap V.V., Konstantinov V.O., Skibitsky V.V., Shaposhnik I.I. Existing problems and new possibilities in the treatment of dyslipidemia Joint Conclusion Based on the Results of the Expert Council. Rational Pharmacotherapy in Cardiology. 2021;17(1):169-172. (In Russ.) https://doi.org/10.20996/1819-6446-2021-02-02
Views:
640
Email this article 